<div id="readability-page-1"><div> <p>(RTTNews) - Tempus AI (TEM) announced the FDA has granted approval for a tumor-only indication for its xT CDx next-generation sequencing platform. The company noted that, with the expanded label, Tempus is the first laboratory to hold FDA companion diagnostic approval for both tumor-only and tumor-normal comprehensive genomic profiling. The  approval paves the way for the company to migrate its entire DNA solid tumor portfolio to FDA-approved assays priced under its current ADLT pricing.</p> <p>&#34;As we have previously highlighted, we expect an estimated $200 ASP benefit beginning in 2027 as a result of this approval,&#34; said Jim Rogers, CFO. </p> <p>In pre-market trading on NasdaqGS, Tempus shares are up 7.39 percent to $55.08.</p> <p>For More Such Health News, visit rttnews.com. </p> <p>The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.</p> </div></div>

ARKG

<p>Tempus AI received FDA approval for the tumor-only indication of its xT CDx platform, becoming the first lab with approvals for both tumor-only and tumor-normal profiling. This enables migration to FDA-approved assays under ADLT pricing, expected to yield a $200 ASP benefit starting in 2027. Tempus shares rose 7.39% to $55.08 in pre-market trading.</p>

nasdaq

Tempus AI

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bear 3X

iShares Genomics Immunology and Healthcare ETF

iShares US Healthcare Providers

VanEck Biotech ETF

ALPS Medical Breakthrough

Proshares UltraShort Nasdaq Biotech

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

Tradr 2X Long TEM Daily ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Nasdaq

Tempus Announces FDA Approval For Tumor Only XT CDx